Fluticasone propionate and salmeterol

(Advair HFA®)

Advair HFA®

Drug updated on 11/28/2023

Dosage FormAerosol (inhalation; fluticasone propionate/salmeterol; 45 mcg/21 mcg, fluticasone propionate/salmeterol; 115 mcg/21 mcg, fluticasone propionate/salmeterol; 230 mcg/21 mcg)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for treatment of asthma in adult and adolescent patients aged 12 years and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Advair HFA (fluticasone propionate and salmeterol) Prescribing Information.2023GlaxoSmithKline, Durham, NC

Randomized Controlled Trials

Clinical Practice Guidelines